Following years of research and investment, liquid biopsies are steadily accumulating FDA approvals. The tests are being used in molecular profiling of solid tumors and as companion diagnostics for targeted cancer therapies.
Thermo Fisher's universal companion diagnostic is nearing approval for NSCLC with the support of multiple pharma partners. The panel is designed to screen 47 genes with one small DNA input.
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.